SEARCH:   Advanced

Blood, 15 November 2007, Vol. 110, No. 10, pp. 3561-3563. Prepublished online as a Blood First Edition Paper on August 2, 2007; DOI 10.1182/blood-2007-07-099481. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-07-099481v1 110/10/3561    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sanchorawala, V. Articles by Seldin, D. C. Search for Related Content PubMed PubMed Citation Articles by Sanchorawala, V. Articles by Seldin, D. C. Related Collections Immunobiology Neoplasia Free Research Articles Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation Vaishali Sanchorawala1,2, Martha Skinner2, Karen Quillen1,3, Kathleen T. Finn1,2, Gheorghe Doros4, and David C. Seldin1,2 1 Stem Cell Transplantation Program of the Section of Hematology-Oncology, 2 Amyloid Treatment and Research Program, Department of Medicine, 3 Department of Pathology and Laboratory Medicine, Boston University School of Medicine; and 4 Department of Biostatistics, Boston University School of Public Health, MA Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago. Seventeen (21%) patients died within the first year of treatment, of treatment-related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared with 50 months for those not achieving a CR (P < .001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Amyloidosis: graviores morbos, asperis remedii Jayesh Mehta Blood 2007 110: 3490-3491. [Full Text] [PDF] This article has been cited by other articles: R. L. Comenzo How I treat amyloidosis Blood, October 8, 2009; 114(15): 3147 - 3157. [Abstract] [Full Text] [PDF] A. V. Kristen, F.-U. Sack, S. O. Schonland, U. Hegenbart, B. M. Helmke, A. Koch, P. A. Schnabel, C. Rocken, S. Hardt, A. Remppis, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis Eur J Heart Fail, October 1, 2009; 11(10): 1014 - 1020. [Abstract] [Full Text] [PDF] G. Palladini and G. Merlini Current treatment of AL amyloidosis Haematologica, August 1, 2009; 94(8): 1044 - 1048. [Full Text] [PDF] S. Girnius, D. C. Seldin, M. Skinner, K. T. Finn, K. Quillen, G. Doros, and V. Sanchorawala Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease Haematologica, July 1, 2009; 94(7): 1029 - 1032. [Abstract] [Full Text] [PDF] L. M. Dember Modern Treatment of Amyloidosis: Unresolved Questions J. Am. Soc. Nephrol., March 1, 2009; 20(3): 469 - 472. [Abstract] [Full Text] [PDF] S. O. Schonland, N. Kroger, C. Wolschke, P. Dreger, A. D. Ho, and U. Hegenbart Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect" Haematologica, March 1, 2009; 94(3): 439 - 441. [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020